Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

Celyad Oncology Reports Q3 Financial Review As Of September 30, The Company Had Cash And Cash Equivalents Of $13.1M; Clinical Updates Expected By End Of Year For The Phase 1 Dose-escalation IMMUNICY-1 Trial For Lead ShRNA-based Allogeneic Car T Candida…

Company continues to transition business focus to monetizing unique cell therapy intellectual property and prioritizing R&D discovery Clinical updates expected by end of year for the Phase 1 dose-escalation

CYAD